Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H1 2018

  • ID: 4473286
  • Report
  • 56 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Grunenthal GmbH
  • Orexigen Therapeutics Inc
  • Serodus ASA
  • MORE
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H1 2018

Summary:

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid receptor is a protein encoded by the OPRL1 (opioid receptor-like 1) gene. NOP receptors are located both pre- and post-synaptically in various areas of CNS. The nociceptin receptor (NOP) and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 7 and 1 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Immunology which include indications Dyskinesia, Substance (Drug) Abuse, Chronic Pain, Neuropathic Pain, Pain, Acute Pain, Alcohol Addiction, Bladder Pain, Cancer Pain, Diabetic Neuropathic Pain, Drug Addiction, Hypersensitivity, Inflammatory Pain, Low Back Pain, Major Depressive Disorder, Osteoarthritis Pain, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD), Pulmonary Arterial Hypertension and Systolic Hypertension.

The latest report Nociceptin Receptor - Pipeline Review, H1 2018, outlays comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)
  • The report reviews Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Grunenthal GmbH
  • Orexigen Therapeutics Inc
  • Serodus ASA
  • MORE
Introduction

Report Coverage

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Overview

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Companies Involved in Therapeutics Development

Blackthorn Therapeutics Inc

Grunenthal GmbH

Orexigen Therapeutics Inc

Serodus ASA

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Drug Profiles

AT-076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-089 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-127 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-326 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTRX-246040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cebranopadol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRT-6010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OREX-1038 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Agonize ORL1 for Acute Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SER-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Dormant Products

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Discontinued Products

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Product Development Milestones

Featured News & Press Releases

Dec 07, 2017: BlackThorn Therapeutics Presents Preclinical and Clinical Data from Its First-in-Class NOPR Antagonist at American College of Neuropsychopharmacology Annual Meeting

Jul 24, 2017: BlackThorn Therapeutics Enrolls First Patient in Phase 2a Study of Lead Compound, BTRX-246040, in Major Depressive Disorder

Jul 10, 2017: Orexigen Announces Presentation of Preclinical Data for OREX-1038 at the International Narcotics Research Conference

Jan 05, 2017: Orexigen Therapeutics Provides Update on OREX-1038 at 35th Annual J.P. Morgan Healthcare Conference

Dec 19, 2016: Serodus: Novel article on SER100 in patients with isolated systolic hypertension is published in Journal of Clinical Pharmacology in Drug Development

Oct 25, 2016: Orphan drug designation for SER100 in Pulmonary Arterial Hypertension granted in U.S.

Sep 30, 2016: Grunenthal’s cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain

Aug 09, 2016: NIH Grant Will Fund Development of Small Molecules for Post-Traumatic Stress Disorder

May 23, 2016: Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory Profile

Apr 18, 2016: PCT SER100 patent application filed - Serodus demonstrates a novel mechanism of action in Pulmonary Hypertension

Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms

Apr 20, 2015: Provisional patent application filed for the Orphan Diseases of Pulmonary Hypertension

Sep 15, 2014: Serodus announces details on the clinical study of SER100 in patients with systolic hypertension

Sep 09, 2014: Serodus Announces Positive Phase IIa Clinical Study Results On SER100 In Patients with Systolic Hypertension

Jun 23, 2014: Serodus Completes The Enrollment Of Patients In Phase IIa Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Blackthorn Therapeutics Inc, H1 2018

Pipeline by Grunenthal GmbH, H1 2018

Pipeline by Orexigen Therapeutics Inc, H1 2018

Pipeline by Serodus ASA, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Blackthorn Therapeutics Inc
  • Grunenthal GmbH
  • Orexigen Therapeutics Inc
  • Serodus ASA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll